Table 2.
Summary of Treatment-Related Adverse Events in All Patients
| Adverse Events | Total (n=27) | Combination Group (n=14) | Monotherapy Group (n=13) | P value* | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Any Grade | Grade 1–2 | Grade 3 | Any Grade | Grade 1–2 | Grade 3 | Any Grade | Grade 1–2 | Grade 3 | ||
| Anorexia | 16 (59.26) | 16 (59.26) | 0 | 12 (85.71) | 12 (85.71) | 0 | 4 (30.77) | 4 (30.77) | 0 | 0.005 |
| Thrombocytopenia | 10 (37.04) | 10 (37.04) | 0 | 7 (50.00) | 7 (50.00) | 0 | 3 (23.08) | 3 (23.08) | 0 | 0.147 |
| Hypertension | 9 (33.33) | 9 (33.33) | 0 | 6 (42.86) | 6 (42.86) | 0 | 3 (23.08) | 3 (23.08) | 0 | 0.249 |
| Diarrhoea | 8 (29.63) | 8 (29.63) | 0 | 4 (28.57) | 4 (28.57) | 0 | 4 (30.77) | 4 (30.77) | 0 | 0.615 |
| Fatigue | 6 (22.22) | 6 (22.22) | 0 | 4 (28.57) | 4 (28.57) | 0 | 2 (15.38) | 2 (15.38) | 0 | 0.362 |
| Anaemia | 5 (18.52) | 5 (18.52) | 0 | 2 (14.29) | 2 (14.29) | 0 | 3 (23.08) | 3 (23.08) | 0 | 0.462 |
| Proteinuria | 3 (11.11) | 3 (11.11) | 0 | 2 (14.29) | 2 (14.29) | 0 | 1 (7.69) | 1 (7.69) | 0 | 0.529 |
| Hand-foot syndrome | 3 (11.11) | 3 (11.11) | 0 | 3 (21.43) | 3 (21.43) | 0 | 0 | 0 | 0 | 0.124 |
| Bleeding | 4 (14.71) | 1 (3.70) | 3 (11.11) | 3 (21.43) | 1 (7.14) | 2 (14.29) | 1 (7.69) | 0 | 1 (7.69) | 0.327 |
Notes: Data were expressed as n (%); *p value of any grade between combination and monotherapy group.